Symbiox Investme

What does Symbiox Investme do?

Symbiox Investment & Trading Co Ltd is a Non Banking Financial Company focused on trading in investments and textiles, with a market cap of Rs 11 Cr and recent net sales of 1 Cr. The company has a P/E ratio of 11.00 and reported no net profit for the latest quarter ending March 2025.

Overview: <BR>Symbiox Investment & Trading Co Ltd operates in the Non Banking Financial Company (NBFC) sector, focusing on trading in investments and textiles.<BR><BR>History: <BR>The company was incorporated in May 1979. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 11 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 11.00 <BR>Industry P/E: 23 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: 0.63% <BR>Price to Book: 0.36<BR><BR>Contact Details: <BR>Address: 7A Rani Rashmoni Road, Kolkata West Bengal: 700013 <BR>Tel: 91-33-32515833 <BR>Email: symbioxinvestment100@gmail.com <BR>Website: http://www.symbioxinvestment.org

Has Symbiox Investme declared dividend?

No Dividend History Available

Who are the peers of the Symbiox Investme?

Symbiox Investme's peers include Bajaj Finance, Jio Financial, Cholaman.Inv.&Fn, Shriram Finance, Muthoot Finance, Libord Securitie, Nexus Surgical, Prism Medico, and BCL Enterprises. Symbiox Investme has below average management risk and capital structure, with a 1-year return of 25.00%.

Peers: The peers of Symbiox Investme are Bajaj Finance, Jio Financial, Cholaman.Inv.&Fn, Shriram Finance, Muthoot Finance, Libord Securitie, Nexus Surgical, Prism Medico, and BCL Enterprises.<BR><BR>Quality Snapshot: Excellent management risk is observed at Bajaj Finance, Cholaman.Inv.&Fn, Muthoot Finance, and the rest. Average management risk is found at Jio Financial, Nexus Surgical, BCL Enterprises, and the rest. Good management risk is noted at Shriram Finance, while below average management risk is present at Symbiox Investme and Prism Medico. Growth is excellent at Jio Financial, while good growth is seen at Bajaj Finance, Cholaman.Inv.&Fn, and BCL Enterprises. Average growth is noted at Symbiox Investme, Shriram Finance, Nexus Surgical, and the rest, while below average growth is present at Prism Medico. Excellent capital structure is observed at Bajaj Finance, Jio Financial, Shriram Finance, Muthoot Finance, Nexus Surgical, and BCL Enterprises, while good capital structure is noted at Cholaman.Inv.&Fn, and below average capital structure is present at Symbiox Investme and Prism Medico.<BR><BR>Return Snapshot: Bajaj Finance has the highest 1-year return at 30.45%, while Jio Financial has the lowest at -20.18%. Symbiox Investme's 1-year return is 25.00%, which is significantly higher than Jio Financial's but lower than Bajaj Finance's. Additionally, Libord Securitie and Prism Medico have negative six-month returns.

What is the technical trend for Symbiox Investme?

As of June 4, 2025, Symbiox Investme's technical trend is neutral with mixed signals, showing a sideways movement influenced by mildly bullish weekly MACD, bearish monthly MACD, bullish Bollinger Bands, and conflicting KST momentum.

As of 4 June 2025, the technical trend for Symbiox Investme has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different indicators. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish, indicating some short-term strength but overall uncertainty. The Bollinger Bands are bullish on both weekly and monthly time frames, suggesting potential upward movement. However, daily moving averages are mildly bearish, which adds to the mixed outlook. The KST shows bearish momentum on the weekly but bullish on the monthly, further contributing to the indecisive trend. Overall, the technical indicators reflect a sideways movement with no strong bullish or bearish bias at this time.

Who are in the management team of Symbiox Investme?

As of March 2022, the management team of Symbiox Investme includes Mina Devi Agarwal, Samit Ray, Mahavir Verma, Bappa Mitra, Rajkumari Naskar, Nitesh Poddar, and Khushboo Pitti, who serve in various executive and independent director roles.

As of March 2022, the management team of Symbiox Investme includes the following individuals:<BR><BR>1. Mina Devi Agarwal - Independent Director<BR>2. Samit Ray - Executive Director<BR>3. Mahavir Verma - Executive Director<BR>4. Bappa Mitra - Independent Director<BR>5. Rajkumari Naskar - Additional Independent Director<BR>6. Nitesh Poddar - Independent Director<BR>7. Khushboo Pitti - Company Secretary & Compliance Officer<BR><BR>These members play various roles within the company's governance and management structure.

Who are the top shareholders of the Symbiox Investme?

The top shareholders of Symbiox Investme include Tyro Commercial Private Limited with 3.2%, Logihaze Solutions Private Limited at 2.47%, and individual investors holding 82.07%. There are no institutional holdings or pledged promoter shares.

The top shareholders of Symbiox Investme include Tyro Commercial Private Limited, which holds the highest promoter stake at 3.2%. The highest public shareholder is Logihaze Solutions Private Limited, with a holding of 2.47%. Additionally, individual investors collectively own a significant 82.07% of the company. There are no institutional holdings or pledged promoter shares reported.

How big is Symbiox Investme?

As of 24th July, Symbiox Investment & Trading Co Ltd has a market capitalization of 8.00 Cr, with Net Sales of 1.04 Cr and a Net Profit of 0.03 Cr for the latest four quarters. The balance sheet as of March 2024 shows Shareholder's Funds of 31.53 Cr and Total Assets of 31.84 Cr.

As of 24th July, Symbiox Investment & Trading Co Ltd has a market capitalization of 8.00 Cr, classifying it as a Micro Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 1.04 Cr and a Net Profit of 0.03 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 31.53 Cr and Total Assets of 31.84 Cr.

When is the next results date for Symbiox Investme?

Symbiox Investme will declare its results on 12 November 2025.

Symbiox Investme is scheduled to declare its results on 12 November 2025.

How has been the historical performance of Symbiox Investme?

Symbiox Investme's historical performance from March 2014 to March 2015 showed increased net sales and operating income, but profitability declined, resulting in a loss after tax and reduced margins. Despite improved cash flow and asset growth, the company faced challenges in maintaining profitability.

Answer:<BR>The historical performance of Symbiox Investme shows a mixed trend over the years, particularly between March 2014 and March 2015.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2015, Symbiox Investme reported net sales of 1.46 Cr, a significant increase from 0.28 Cr in March 2014. The total operating income also rose to 1.46 Cr from 0.28 Cr, reflecting improved business activity. However, total expenditure increased to 1.44 Cr from 0.27 Cr, leading to an operating profit (PBDIT) of 0.02 Cr, slightly up from 0.01 Cr in the previous year. Despite this, the profit before tax remained low at 0.02 Cr, compared to 0.01 Cr in March 2014. The company faced a loss in profit after tax, reporting -0.09 Cr in March 2015, down from a profit of 0.01 Cr in the prior year. The earnings per share (EPS) also declined to -0.03 from 0.01. The operating profit margin decreased to 1.58% from 4.23%, while the profit after tax margin fell to -6.11% from 5.28%. On the balance sheet, total assets were reported at 31.97 Cr in March 2025, showing a slight increase from 31.84 Cr in March 2024. The company maintained no long-term borrowings and reported a book value per share of 10.14 in March 2025, up from 10.08 in March 2024. Cash flow from operating activities improved to 3.00 Cr in March 2025, reversing a negative trend from the previous year. Overall, while there were increases in sales and operating income, the company struggled with profitability and margins during this period.

Is Symbiox Investme overvalued or undervalued?

As of December 4, 2025, Symbiox Investme is considered very expensive and overvalued, with a negative PE ratio of -872.92 and a year-to-date return of -48.52%, significantly underperforming compared to its peers and the Sensex.

As of 4 December 2025, the valuation grade for Symbiox Investme has moved from risky to very expensive, indicating a significant deterioration in its perceived value. The company is currently overvalued, with a PE ratio of -872.92, an EV to EBIT ratio of 5.40, and a Price to Book Value of 0.27. These ratios highlight the company's struggles, particularly with a negative PE ratio and a concerning return on equity of -0.03%.<BR><BR>In comparison to its peers, Symbiox Investme stands out unfavorably. For instance, Bajaj Finance has a PE ratio of 34.9, while Life Insurance boasts a much more attractive PE of 10.85. The stark contrast in valuation metrics suggests that Symbiox is not only overvalued but also significantly underperforming relative to its industry peers. Additionally, the company's stock has underperformed against the Sensex, with a year-to-date return of -48.52% compared to the Sensex's positive return of 9.12%. This further reinforces the notion that Symbiox Investme is not a favorable investment at this time.

Are Symbiox Investment & Trading Co Ltd latest results good or bad?

Symbiox Investment & Trading Co Ltd's latest results are concerning, showing a 33.3% decline in annual sales to ₹2.00 crores and zero net profit, alongside a poor return on equity of 0.85% and a 1-year stock return of -52.79%. Overall, these indicators suggest significant challenges and a negative trend for the company.

Symbiox Investment & Trading Co Ltd's latest results are concerning and indicate a negative trend. For FY25, the company reported annual sales of ₹2.00 crores, which represents a significant decline of 33.3% year-on-year from ₹3.00 crores in FY24. This decline highlights a lack of revenue stability and growth.<BR><BR>Moreover, the company has consistently struggled with profitability, reporting zero net profit across multiple fiscal years. The average return on equity (ROE) is a dismal 0.85%, indicating weak capital efficiency. Additionally, the stock has severely underperformed, with a 1-year return of -52.79%, contrasting sharply with the Sensex's gain of 7.07% during the same period.<BR><BR>The financial performance reflects persistent stagnation, with no meaningful operational scale or strategic direction. The absence of institutional investors and minimal promoter holding further raises concerns about management's commitment and the company's future prospects.<BR><BR>Overall, the latest results can be characterized as bad, with multiple red flags indicating significant challenges for the company moving forward.

Should I buy, sell or hold Symbiox Investment & Trading Co Ltd?

Why is Symbiox Investment & Trading Co Ltd falling/rising?

As of 17-Mar, the stock price of Symbiox Investment & Trading Co Ltd is rising to 1.68, reflecting a 7.01% increase after two days of decline, indicating a potential trend reversal. Despite this short-term rise and increased investor participation, the stock remains below its moving averages, suggesting a longer-term bearish trend.

As of 17-Mar, the stock price of Symbiox Investment & Trading Co Ltd is rising, currently at 1.68, which reflects an increase of 0.11 or 7.01%. This upward movement comes after two consecutive days of decline, indicating a potential trend reversal. Additionally, the stock has outperformed its sector by 6.21% today, suggesting positive momentum in comparison to its peers.<BR><BR>Investor participation has also increased, with a delivery volume of 15.13 k on 16 March, which is up by 12.91% compared to the 5-day average delivery volume. This rise in trading activity may indicate growing interest among investors, contributing to the stock's price increase.<BR><BR>However, it is important to note that despite the current rise, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which typically suggests a bearish trend in the longer term. Overall, the combination of a short-term price increase, improved investor participation, and sector outperformance are key factors contributing to the current rise in Symbiox Investment & Trading Co Ltd's stock price.

Why is Symbiox Investment & Trading Co Ltd falling/rising?

As of 18-Mar, Symbiox Investment & Trading Co Ltd's stock price is rising to 1.73, reflecting a 2.98% increase. Despite recent gains, the stock has a concerning long-term decline of over 52% in the past year, and falling investor participation may impact future price movements.

As of 18-Mar, Symbiox Investment & Trading Co Ltd's stock price is rising, currently at 1.73, which reflects a change of 0.05 or 2.98% increase. This upward movement can be attributed to the stock's performance over the last two days, during which it has gained 10.19%. Additionally, it has outperformed the sector by 1.63% today. <BR><BR>In the context of recent performance, the stock has shown a significant increase of 6.79% over the past week, contrasting sharply with the Sensex, which has declined by 0.21% in the same period. However, it is important to note that while the stock is experiencing a short-term rise, its longer-term performance remains concerning, with a decline of 52.21% over the past year and 56.20% over the past three years.<BR><BR>Despite the recent gains, there are signs of falling investor participation, as evidenced by a delivery volume of 4.13k on 17 March, which is down by 67.66% compared to the five-day average. This decline in participation could indicate a lack of sustained interest from investors, which may affect future price movements. Overall, while the stock is currently rising, the broader context of its performance and investor engagement suggests a complex situation.

Why is Symbiox Investment & Trading Co Ltd falling/rising?

As of 19-Mar, Symbiox Investment & Trading Co Ltd's stock price is rising to 1.78, reflecting a 2.89% increase. This short-term gain contrasts with significant long-term declines, suggesting a temporary rebound amid broader sector challenges.

As of 19-Mar, Symbiox Investment & Trading Co Ltd's stock price is rising, currently at 1.78, with a change of 0.05 (2.89%) increase. This upward movement can be attributed to several factors. The stock has outperformed its sector by 6.73% today and has been on a consecutive gain streak for the last three days, accumulating a total return of 13.38% during this period. Additionally, the stock's performance over the past week shows a positive return of 3.49%, contrasting with a decline of 2.40% in the Sensex.<BR><BR>Despite the overall negative trends in the longer-term performance, such as a 49.14% decline over the past year and a 54.94% drop over three years, the recent short-term gains indicate a temporary rebound. However, it is important to note that the stock's moving averages are higher than the 5-day moving average but lower than the 20-day, 50-day, 100-day, and 200-day moving averages, suggesting that while there is a short-term rise, it may not yet indicate a long-term recovery.<BR><BR>Moreover, the finance/NBFC sector has experienced a decline of 3.85%, which could imply that the stock's rise is somewhat isolated from broader sector trends. However, the falling investor participation, with a delivery volume decrease of 6.8% against the 5-day average, may indicate caution among investors despite the recent price increase. Overall, the combination of recent performance gains and sector outperformance contributes to the current rise in Symbiox Investment & Trading Co Ltd's stock price.

Why is Symbiox Investment & Trading Co Ltd falling/rising?

As of 20-Mar, Symbiox Investment & Trading Co Ltd's stock price is currently at 1.80, showing a recent upward trend with a 6.51% gain over the past week. However, despite short-term gains, longer-term performance has declined significantly, and decreased investor participation may indicate caution.

As of 20-Mar, Symbiox Investment & Trading Co Ltd's stock price is rising, currently at 1.80, with a change of 0.02 (1.12%) upwards. The stock has shown a strong performance over the past week, gaining 6.51%, while the benchmark Sensex has remained nearly flat with a change of -0.04%. Additionally, the stock has been on a consecutive gain streak for the last four days, accumulating a total return of 14.65% during this period.<BR><BR>Despite a decline in performance over longer time frames, such as a 3.23% drop over the past month and a significant 46.43% decrease over the past year, the recent short-term gains indicate a positive shift in investor sentiment. However, it is important to note that there has been a decrease in investor participation, with delivery volume falling by 71.54% compared to the 5-day average, which may suggest caution among investors.<BR><BR>Overall, the stock's recent upward movement can be attributed to its outperformance against the sector today and the positive momentum built over the last few days, despite the challenges reflected in longer-term performance metrics.

Why is Symbiox Investment & Trading Co Ltd falling/rising?

As of 23-Mar, the stock price of Symbiox Investment & Trading Co Ltd is at 1.79, down 0.56% after a trend reversal following four days of gains. The stock has underperformed year-to-date and over the past year, influenced by a broader sector downturn and decreased investor participation.

As of 23-Mar, the stock price of Symbiox Investment & Trading Co Ltd is currently at 1.79, reflecting a change of -0.01, or a decrease of 0.56%. This decline comes after a trend reversal, as the stock had experienced four consecutive days of gains prior to this drop. Additionally, the stock has underperformed in the longer term, with a year-to-date decrease of 1.10% and a significant decline of 47.51% over the past year. <BR><BR>Despite today's performance showing that the stock has outperformed its sector by 3.24%, the overall sentiment is affected by a broader downturn in the Finance/NBFC sector, which has fallen by 3.81%. Furthermore, there is a notable decrease in investor participation, with the delivery volume on March 20 dropping by 80.09% compared to the five-day average. This lack of investor engagement may contribute to the stock's current downward movement. <BR><BR>In terms of moving averages, while the stock is higher than the 5-day and 20-day moving averages, it remains lower than the 50-day, 100-day, and 200-day moving averages, indicating a potential bearish trend in the longer term. Overall, the combination of sector performance, declining investor participation, and the recent trend reversal are key factors contributing to the stock's current decline.

Why is Symbiox Investment & Trading Co Ltd falling/rising?

As of 24-Mar, Symbiox Investment & Trading Co Ltd's stock price is declining at 1.65, down -7.82%, with a year-to-date drop of -8.84%. The stock is underperforming compared to the benchmark Sensex and shows reduced investor interest, contributing to its bearish trend.

As of 24-Mar, Symbiox Investment & Trading Co Ltd is experiencing a decline in its stock price, currently at 1.65, which reflects a change of -0.14 or -7.82%. The stock has been underperforming, having lost -8.33% over the last two days, contributing to a year-to-date decline of -8.84%. <BR><BR>In comparison to the benchmark Sensex, which has also seen a negative return of -13.09% year-to-date, Symbiox's performance is notably worse, particularly over the past year where it has dropped -49.23%. The stock is trading below its moving averages across various time frames, indicating a bearish trend. <BR><BR>Additionally, there has been a significant decrease in investor participation, with delivery volume falling by -26.81% compared to the 5-day average. This lack of trading activity suggests reduced interest in the stock, further contributing to its decline. Meanwhile, the finance/NBFC sector has gained by 2.38%, highlighting that the stock's poor performance is not reflective of broader sector trends. Overall, these factors collectively explain the downward movement in Symbiox Investment & Trading Co Ltd's stock price.

Why is Symbiox Investment & Trading Co Ltd falling/rising?

As of 25-Mar, the stock price of Symbiox Investment & Trading Co Ltd is 1.65, unchanged from the previous session. The stock has been on a downward trend, declining 50.89% over the past year and trading below all key moving averages, indicating a bearish outlook.

As of 25-Mar, the stock price of Symbiox Investment & Trading Co Ltd is currently at 1.65, with no change from the previous trading session. The stock has been experiencing a downward trend, as evidenced by its performance over various periods. Over the past week, the stock has fallen by 4.62%, and over the last month, it has decreased by 8.33%. Year-to-date, the stock is down 8.84%, and it has significantly underperformed over the past year, with a decline of 50.89%.<BR><BR>Additionally, the stock is trading below its moving averages across all time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Despite a notable increase in investor participation, with delivery volume rising by 369.05% against the 5-day average, the stock has underperformed its sector by 2.92%. <BR><BR>Overall, the combination of consistent declines in stock price, underperformance relative to the sector, and trading below key moving averages contributes to the perception that Symbiox Investment & Trading Co Ltd is currently in a falling trend.

Which are the latest news on Symbiox Investme?